Frequently Asked Questions

The Depo-Provera lawsuit alleges that Pfizer, the manufacturer of Depo-Provera (medroxyprogesterone acetate), failed to adequately warn patients and doctors about the risk of developing meningioma brain tumors from long-term use. A 2024 BMJ study found a 5.6x increased risk of meningioma after one or more years of use. Over 3,099 cases are now consolidated in MDL 3140 in the Northern District of Florida.

You may qualify if you: (1) received two or more Depo-Provera or generic medroxyprogesterone injections, (2) were diagnosed with a meningioma brain tumor confirmed by MRI or imaging, (3) are within your state's statute of limitations, and (4) have not already retained a law firm for this claim.

Yes. The active ingredient is the same — medroxyprogesterone acetate — regardless of whether you received the brand-name or generic version. The risk is associated with the drug compound, not the brand. Claims involving generic versions are included in MDL 3140.

No. Attorneys handling Depo-Provera cases work on a contingency fee basis. This means the attorney only gets paid if you receive compensation — typically a percentage of your settlement or award. There is no upfront cost for a case evaluation or for filing a claim.

No settlements have been reached yet in MDL 3140 as of March 2026. The first bellwether trial is scheduled for December 2026, and its outcome will significantly influence settlement discussions. Settlement values will depend on individual factors including injury severity, treatment required (particularly whether neurosurgery was needed), and medical expenses incurred. Be cautious of anyone claiming to know specific settlement amounts at this stage.

MDL 3140 is a multidistrict litigation that consolidates all federal Depo-Provera meningioma lawsuits before Judge M. Casey Rodgers in the Northern District of Florida. An MDL is not a class action — each plaintiff maintains their own individual case. The consolidation allows common issues like scientific evidence and corporate conduct to be handled efficiently.

Yes. Every state has a statute of limitations — a legal deadline after which you lose the right to file. Most states allow 2-3 years from the date of diagnosis or the date you learned your meningioma may be connected to Depo-Provera (this is called the 'discovery rule'). Some states have shorter deadlines. Missing this deadline means you cannot file regardless of how strong your case is.

At this stage of the litigation, a confirmed meningioma diagnosis is required to file a claim. If you used Depo-Provera for an extended period, consider discussing your medication history with your doctor, particularly if you experience persistent headaches, vision changes, or cognitive difficulties. Early detection through MRI screening can identify meningiomas before they cause significant symptoms.

Mass tort litigation typically takes several years from filing to resolution. The first bellwether trial in MDL 3140 is scheduled for December 2026. If a global settlement is reached, it could take 1-3 years after that for payments to be distributed. Filing early ensures you don't miss deadlines and positions your case for any future settlement.

Most plaintiffs in mass tort litigation never appear in court. The MDL process handles common issues centrally, and the vast majority of cases resolve through settlement rather than individual trials. If your specific case is selected as a bellwether, you may need to participate more actively, but this applies to only a small number of cases.

The key documentation includes: (1) records of your Depo-Provera or medroxyprogesterone injections — pharmacy records, insurance claims, or doctor's records, (2) medical records confirming your meningioma diagnosis — MRI reports, pathology reports, surgical records, and (3) records of treatment received and expenses incurred. Your attorney will help you gather these records.

Yes. A successful surgery or treatment does not disqualify you from filing a claim. In fact, the costs, risks, and recovery time associated with neurosurgery are significant components of potential compensation. Ongoing monitoring requirements, risk of recurrence, and impact on quality of life are also relevant factors.

Meningiomas are known to express progesterone receptors. Medroxyprogesterone acetate — the synthetic progestin in Depo-Provera — binds to these receptors and may stimulate tumor growth. Unlike oral contraceptives metabolized daily, injectable medroxyprogesterone creates sustained elevated hormone levels for three months per injection. A 2024 BMJ study confirmed the link with a 5.6x increased risk after one or more years of use.

This is a central question in the litigation. Plaintiffs allege that scientific evidence linking medroxyprogesterone to meningioma was available for years before the FDA acted. France's regulatory agency (ANSM) restricted medroxyprogesterone use before the US FDA took any action. Plaintiffs argue Pfizer had access to the underlying data and should have updated its warnings decades earlier.

No. We are a legal information resource that publishes educational content about active litigation. We do not provide legal advice, represent clients, or practice law. When you submit an inquiry through our site, your information is shared with attorneys who specialize in Depo-Provera litigation and who can evaluate your specific situation.